European Regulators Find Possible Link Between AstraZeneca COVID-19 Vaccine and Rare Clotting Disorder
(LONDON) — The European Union’s drug agency said Wednesday that it found a “possible link” between the AstraZeneca coronavirus vaccine and a rare clotting disorder but recommended that vaccinations continue in adults, saying the benefits of the shot still outweigh risks. The European Medicines Agency described the clots as “very rare” side effects. It said most of the cases reported have occurred in women under 60 within two weeks of vaccination — but based on the currently available evidence, it was not able to identify specific risk factors. Experts reviewed several dozen cases that came mainly from Europe and the United Kingdom, where around 25 million people have received the AstraZeneca vaccine. “The reported cases of unusual blood clotting following vaccination with the AstraZeneca vaccine should be listed as possible side effects of the vaccine,” said Emer Cooke, the agency’s executive director. But it placed no new age restrictions on using the vaccine in people 18 and over, as some countries have done. “The risk of mortality from COVID is much greater than the risk of mortality from these side effects.,” Cooke said. The EMA, the World Health Organization and numerous other health authorities have said repeatedly that the AstraZeneca vaccine is safe and effective and that the protection it offers against COVID-19 outweighs the small risks of rare blood clots — a message the EMA repeated Wed...
Authors: Reissier S, Cattoir V Abstract INTRODUCTION: Streptogramins (pristinamycin and quinupristin-dalfopristin) can be interesting options for the treatment of infections due to Gram-positive cocci, especially multidrug-resistant isolates. AREAS COVERED: This review provides an updated overview on structural and activity characteristics, mechanisms of action and resistance, pharmacokinetic/pharmacodynamic and clinical use of streptogramins. EXPERT OPINION: The streptogramin antibiotics act by inhibition of the bacterial protein synthesis. They are composed of two chemically distinct compounds, namely typ...
Publication date: Available online 10 October 2020Source: American Journal of Kidney DiseasesAuthor(s): Shreeram Akilesh, Cynthia C. Nast, Michifumi Yamashita, Kammi Henriksen, Vivek Charu, Megan L. Troxell, Neeraja Kambham, Erika Bracamonte, Donald Houghton, Naila I. Ahmed, Chyi Chyi Chong, Bijin Thajudeen, Shehzad Rehman, Firas Khoury, Jonathan E. Zuckerman, Jeremy Gitomer, Parthassarathy C. Raguram, Shanza Mujeeb, Ulrike Schwarze, M. Brendan Shannon
CONCLUSION: In this study, no influence of tear substitutes containing different viscosities of hyaluronic acid on the measurement results of optical coherence tomography could be determined. Therefore, 0.1%, 0.2% and 0.3% hyaluronic acid can be applied to the patient to improve the corneal surface before the examination with optical coherence tomography, without influencing the measurement results of optical coherence tomography. PMID: 33036058 [PubMed - as supplied by publisher]
Publication date: Available online 9 October 2020Source: Cirugía Española (English Edition)Author(s): Victoria Lucas-Guerrero, Mireia Pascua-Solé, José Luis Ramos Rodríguez, Anna Trinidad Borrás, Carlos González de Pedro, José María Jover Navalón, Pere Rebasa, Eduardo M. Targarona Soler, Xavier Serra-Aracil, on behalf of the Comisión Nacional de la Especialidad de Cirugía General y del Aparato Digestivo, de la Sección de Formación de la Asociación Española de Cirujanos
Publication date: Available online 9 October 2020Source: Reumatología Clínica (English Edition)Author(s): Lina María Saldarriaga Rivera, Daniel Fernández Ávila, Wilson Bautista Molano, Daniel Jaramillo Arroyave, Alain Jasaf Bautista Ramírez, Adriana Díaz Maldonado, Jorge Hernán Izquierdo, Edwin Jáuregui, María Constanza Latorre Muñoz, Juan Pablo Restrepo, Juan Sebastián Segura Charry
CONCLUSIONS: This single practice study showed total patient contact was similar over both sample periods, but most contact in 2020 was virtual. Further longitudinal multi-practice studies to confirm these findings and describe future consultation patterns are needed to inform general practice service delivery post-COVID-19. PMID: 33032304 [PubMed - in process]
Publication date: Available online 1 October 2020Source: Academic RadiologyAuthor(s): Neo Poyiadji, Chad Klochko, Jeff LaForce, Manuel L. Brown, Brent Griffith
Curious what people think with pandemic and lack of away rotations.
Authors: Zhao N, Xiang Q, Liu Z, Zhao X, Cui Y Abstract INTRODUCTION: There remains an unmet need for better anticoagulants. The phase I clinical trial is of great significance in the development of anticoagulants, and the design is special. This system review aims to provide insights for the design of future phase I clinical trials of anticoagulants. AREAS COVERED: We searched the database PubMed and ClinicalTrail.gov website, to collate the phase I clinical trial of anticoagulants in healthy people. The study protocol, inclusion exclusion criteria, safety and pharmacodynamic indexes were reviewed. EXPERT ...
More News: 1918 Spanish Flu | AstraZeneca | Bleeding | Brain | Children | Coronavirus | COVID-19 | European Medicines Agency (EMA) | France Health | Germany Health | Health | International Medicine & Public Health | Italy Health | Neurology | Nurses | Nursing | Oxford University | Pandemics | Polio | Polio Vaccine | South Korea Health | Spain Health | Study | Teachers | UK Health | Vaccines | WHO | Women